Elan Liabilities 2025

Elan Aktienanalyse

What does Elan do?

Elan Corp is an Irish pharmaceutical company specializing in the research, development, and marketing of medications for neurological and autoimmune diseases. The company was founded in 1969 under the name Athlone Laboratories and has since undergone significant changes in both its business fields and its name. In 1996, the company was renamed Elan Corporation, a name it still holds today. At that time, the company primarily focused on researching and developing medications for Alzheimer's and Parkinson's diseases. However, in the following years, the company shifted its focus more towards treating autoimmune diseases such as multiple sclerosis and Crohn's disease. Elan Corp's business model is based on the development of medications through research and development as well as the acquisition of established therapeutics. One key component of the product portfolio is the medication Tysabri, which was developed in collaboration with Biogen Idec. It is used to treat multiple sclerosis patients and is one of Elan's top-selling medications, contributing significantly to the company's success. Elan Corp consists of three main business areas: 1. Biopharmaceuticals This division is responsible for the research and development of medications for neurological diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. Some of the key products in this area, in addition to Tysabri, include Axona, a nutritional supplement to enhance cognitive function in Alzheimer's patients, and Zanaflex, which is used to treat muscle spasms in the majority of multiple sclerosis patients. 2. Neurology In this division, Elan focuses on the marketing and distribution of nerve and pain medications, as well as products for treating infections. Some of the key products in this area are Skelaxin, a muscle relaxant for pain and muscle spasms, and Biaxin, an antibiotic for treating infections. 3. Medical Technology Elan Corp's medical technology division specializes in the development and marketing of infusion pumps. The company primarily offers its products and services in the United States and Europe and holds a strong position in this market. Elan Corp is a company with a strong focus on research and development. Its key products are medications for treating neurological and autoimmune diseases, with Tysabri being the most well-known and successful. The company has undergone significant changes over the years and now focuses on developing medications for autoimmune diseases in the neurology field. With a strong emphasis on research and development, as well as the acquisition of established therapeutics, Elan Corp is an important player in the pharmaceutical industry and is expected to continue growing and succeeding in the future. Elan ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Elan's Liabilities

Elan's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Elan's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Elan's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Elan's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Elan’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Elan stock

What is the level of liabilities of Elan this year?

Elan has a debt balance of 8.18 B JPY this year.

What were the liabilities of Elan compared to the previous year?

The liabilities of Elan have increased by 15.48% increased compared to the previous year.

What are the consequences of high debt for investors of Elan?

High liabilities can pose a risk for investors of Elan, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Elan?

Low liabilities mean that Elan has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Elan affect the company?

An increase in liabilities of Elan can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Elan affect the company?

A decrease in the liabilities of Elan can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Elan?

Some factors that can influence the liabilities of Elan include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Elan so important for investors?

The liabilities of Elan are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Elan take to modify the liabilities?

To change its liabilities, Elan can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Elan pay?

Over the past 12 months, Elan paid a dividend of 13 JPY . This corresponds to a dividend yield of about 1.73 %. For the coming 12 months, Elan is expected to pay a dividend of 15.1 JPY.

What is the dividend yield of Elan?

The current dividend yield of Elan is 1.73 %.

When does Elan pay dividends?

Elan pays a quarterly dividend. This is distributed in the months of January, January, January, January.

How secure is the dividend of Elan?

Elan paid dividends every year for the past 13 years.

What is the dividend of Elan?

For the upcoming 12 months, dividends amounting to 15.1 JPY are expected. This corresponds to a dividend yield of 2.01 %.

In which sector is Elan located?

Elan is assigned to the 'Health' sector.

Wann musste ich die Aktien von Elan kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Elan from 3/1/2025 amounting to 14 JPY, you needed to have the stock in your portfolio before the ex-date on 12/27/2024.

When did Elan pay the last dividend?

The last dividend was paid out on 3/1/2025.

What was the dividend of Elan in the year 2024?

In the year 2024, Elan distributed 13 JPY as dividends.

In which currency does Elan pay out the dividend?

The dividends of Elan are distributed in JPY.